<p>投资者长期以来一直试图通过市场定时来最大化收益——低买高卖。然而，在相对短期的交易或投资中取得成功通常需要精确的买卖时机。由于经纪费和税收，这可能是一个具有挑战性和成本高昂的提议。</p>
<p>许多投资者可能不再试图把握市场时机，而是希望专注于进行长期投资，这可能会在长期内提供更大（且更有税收优势）的收益。对于那些在投资旅程中还有几十年时间的人来说，持有一个多样化的股票组合对个人投资者的心态和财富增长潜力都有很大帮助。</p>
<p>尽管被动指数基金是考虑的好选择，在这方面，我认为有一些蓝筹股是长期持有的完美选择，适合那些喜欢挑选个股的人。这三家公司是我认为可以在大多数市场环境中成为潜在表现优异者的长期持有者。</p>
<h2>本文要点：</h2>
<ul>
<li>长期投资需要选择适合投资者持有并耐心等待的正确股票，具有适当风险配置。</li>
<li>以下三家公司似乎有望继续提供稳定持续的回报，值得考虑长达十年（或更长）的持有。</li>
<li>如果你正在寻找一些潜力巨大的股票，请务必获取我们全新的 “下一个英伟达” 报告的免费副本。其中包括我们确信具有 10 倍潜力的软件股票。</li>
</ul>
<h2>Meta Platforms（Meta）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/06/imageForEntry24-FF6.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/06/imageForEntry24-FF6.jpg"/></p>
<p>Meta Platforms 标志在一栋办公楼前的标志牌上</p>
<p><strong>Meta Platforms</strong>（纳斯达克：META）是一家顶级社交媒体巨头，无需多介绍。这家脸书和 Instagram 巨头拥有一个稳固的核心业务，像少数其他公司一样产生现金流。因此，该公司最近的飙升主要归功于基本面——这是许多顶级成长股所不能夸耀的。</p>
<p>在公司最近的一个季度中，Meta 宣布将扩大其人工智能支出，现在预计仅今年将花费 370 至 400 亿美元。这一加大的资本支出计划是首席执行官马克·扎克伯格为了在年底前将 Meta 转变为全球顶尖人工智能公司而采取的举措。</p>
<p>这是一个雄心勃勃的目标，投资者肯定在关注。然而，这并不是说该公司强劲的核心业务就无足轻重。该公司的 Q2 2024 年收入为 391 亿美元，比五年前高出 136%，全球数字广告市场预计以 15.5% 的年增长率增长。Meta 的营运利润率达到令人印象深刻的 38%，其应用部门实现了 50% 的利润率，突显了 Meta 的显著盈利能力和增长潜力。</p>
<p>Meta 在上半年创造了 234 亿美元的自由现金流，首席执行官马克·扎克伯格将其投资于股票回购和股息。作为科技和互联网领域的领导者，Meta 正在大力投资于人工智能，包括 Meta AI 聊天机器人用于创建图像和处理各种用户提示。Meta 庞大的用户群体达到了 32.7 亿日活跃应用用户，通过显著的参与度和网络效应增强了其对广告商的吸引力。</p>
<h2>强生（Johnson &amp; Johnson）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2021/02/imageForEntry20-M70.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2021/02/imageForEntry20-M70.jpg"/></p>
<p>强生（Johnson &amp; Johnson）标志在公司办公楼外的标志牌上</p>
<p><strong>强生（Johnson &amp; Johnson）</strong>（纽约证券交易所：JNJ）以其稳定性和可靠的股息而闻名，并继续是股息投资者的强劲选择。尽管最近存在法律问题并且分拆了其消费者健康部门，但该公司在制药、医疗器械和消费品领域保持着多样化的收入基础。JNJ 股票的股息率为 3.1%，五年股息增长率超过 6%，为投资者提供持续的股息增长和弹性股价。这使得这家制药巨头对许多寻求通过股息增值来复利其收益的投资者具有吸引力。</p>
<p>值得注意的是，强生最近同意收购 V-Wave Ltd.，一家开发心力衰竭治疗方案的公司，支付了 6 亿美元的前期款项以及最高达 11 亿美元的额外支付。V-Wave 将成为强生医疗技术的一部分，增强其在心血管创新领域的作用并扩大其市场份额。</p>
<p>该股票稳定的表现得到了强劲的收益和对高增长领域（如肿瘤学和免疫学）的关注的支持。强生最近分拆 Kenvue，使 J&amp;J 能够专注于核心业务，潜在增强增长。分拆后，分析师持乐观态度。我认为公司强大的药物管线可能会提升收入，而持续的法律解决方案将进一步稳定这一名称。</p>
<h2>辉瑞（Pfizer）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2021/12/imageForEntry83-3Qa.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2021/12/imageForEntry83-3Qa.jpg"/></p>
<p>辉瑞标志在公司大楼外</p>
<p>2024 年初，<strong>辉瑞</strong>（纽约证券交易所：PFE）看到了来自 Prevnar 和 Eliquis 等关键产品的非 COVID 收入增长。该公司还进行了多项重要产品推出和收购，包括收购 Nurtec 和 Seagen 资产。这一趋势预计将在长期内持续。但这并不意味着辉瑞不关心其底线。随着持续进行的削减成本和重组计划，辉瑞旨在在 2024 年节省 40 亿美元。</p>
<p>该公司继续提供强劲的 5.8% 股息率，坚定地致力于定期支付给收入投资者，这些投资者很高兴等待大型制药领域的另一波牛市。</p>
<p>在公司最近的财报中，辉瑞将其 2024 年调整后的每股收益指引提高至 2.45 美元至 2.65 美元，高于 2.25 美元，并将其营收预测提升至 595 亿至 625 亿美元，较 2023 年增长 4%。该股票的吸引力在于其行业领先地位、创新记录和引人注目的价值，前瞻市盈率为 11 倍，股息率高达 5.8%，基于每季度 0.42 美元的股息。</p>
<p>公司旨在通过展示其长期战略取得进展来恢复投资者信心。在第二季度财报中，营收同比增长 3%，或者在排除下降的 COVID-19 项目 Comirnaty 和 Paxlovid 后增长 14%。这一增长得益于 Vyndaqel、Eliquis 和最近收购的 Seagen 的强劲销售，以及对 Nurtec 需求的增加。辉瑞的成本调整努力旨在到年底节省 40 亿美元，为成功做出了贡献，第二季度调整后每股收益为 0.60 美元，超过了华尔街的 0.46 美元预期。</p>
<h2><strong>参加这个退休问卷，立即与顾问匹配（赞助内容）</strong></h2>
<p>您准备好退休了吗？规划退休可能让人感到不知所措，这就是为什么今天与一位受托人理财顾问讨论您的目标可能是个好主意。</p>
<p>从 SmartAsset 这里开始参加这个退休问卷，它将在 5 分钟内为您匹配最多 3 位服务您所在地区及周边地区的理财顾问。Smart Asset 目前每月为超过 5 万人提供匹配。</p>
<p>立即点击这里开始。</p>
<p>这篇文章最初发表在 24/7 Wall St.上，介绍了目前值得长期持有的 3 支最佳股票。</p>

META

<p>这篇文章介绍了三只长期股票的选择，推荐给那些希望增加财富而不试图预测市场的投资者。文章强调了 Meta Platforms（META）因其强大的核心业务和重大的人工智能投资；强调了强生公司（Johnson & Johnson，JNJ）因其稳定性、可靠的股息以及最近收购心脏治疗开发公司 V-Wave Ltd.；并建议考虑蓝筹股作为多元化长期投资策略的一部分</p>

<p>Investors have long sought to maximize gains by timing the market – buying low and selling high. However, success in trading, or investing over relatively short-term time frames, generally requires precise timing on both ends. That can be a challenging and costly proposition due to brokerage fees and taxes.</p>
<div class="lb-trans"><p>投资者长期以来一直试图通过市场定时来最大化收益——低买高卖。然而，在相对短期的交易或投资中取得成功通常需要精确的买卖时机。由于经纪费和税收，这可能是一个具有挑战性和成本高昂的提议。</p>
</div><p>Instead of trying to time the market, many investors may want to focus instead on making long-term investments that may provide greater (and more tax-advantaged) gains over the long-term. For those with decades ahead on their investing journey, sitting on a well-diversified portfolio of stocks can do wonders for an individual investor’s mindset and wealth-building potential.</p>
<div class="lb-trans"><p>许多投资者可能不再试图把握市场时机，而是希望专注于进行长期投资，这可能会在长期内提供更大（且更有税收优势）的收益。对于那些在投资旅程中还有几十年时间的人来说，持有一个多样化的股票组合对个人投资者的心态和财富增长潜力都有很大帮助。</p>
</div><p>While passive index funds are great options to consider in this regard, there are a number of blue-chip stocks I think make perfect long-term holdings for those stock pickers out there. These three companies are ones I’d put in the long-term bucket as potential out-performers in most market environments.</p>
<div class="lb-trans"><p>尽管被动指数基金是考虑的好选择，在这方面，我认为有一些蓝筹股是长期持有的完美选择，适合那些喜欢挑选个股的人。这三家公司是我认为可以在大多数市场环境中成为潜在表现优异者的长期持有者。</p>
</div><h2>Key Points About This Article:</h2>
<ul>
<li>Long-term investing requires picking the right stocks with the appropriate risk profiles for investors to sit on and be patient with.</li>
<li>The following three companies appear poised to continue to provide consistent and steady returns over the long-haul, and are worth considering for a decade-long hold (or more).</li>
<li>If you’re looking for some stocks with huge potential, make sure to grab a free copy of our <strong>brand-new “The Next NVIDIA” report</strong>. It features a software stock we’re confident has 10X potential.</li>
</ul>
<div class="lb-trans"><h2>本文要点：</h2>
<ul>
<li>长期投资需要选择适合投资者持有并耐心等待的正确股票，具有适当风险配置。</li>
<li>以下三家公司似乎有望继续提供稳定持续的回报，值得考虑长达十年（或更长）的持有。</li>
<li>如果你正在寻找一些潜力巨大的股票，请务必获取我们全新的 “下一个英伟达” 报告的免费副本。其中包括我们确信具有 10 倍潜力的软件股票。</li>
</ul>
</div><h2>Meta Platforms (META)</h2>
<div class="lb-trans"><h2>Meta Platforms（Meta）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/06/imageForEntry24-FF6.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2022/06/imageForEntry24-FF6.jpg"/></p>
<p>Meta Platforms logo on a sign in front of an office building</p>
<div class="lb-trans"><p>Meta Platforms 标志在一栋办公楼前的标志牌上</p>
</div><p><strong>Meta Platforms</strong>(NASDAQ:META) is a top social media giant that really doesn’t need any introduction. The Facebook and Instagram giant has a solid core business which spits off cash flow like few others in the market. Accordingly, the company’s recent surge can be attributed mostly to fundamentals – something many top growth stocks can’t boast.</p>
<div class="lb-trans"><p><strong>Meta Platforms</strong>（纳斯达克：META）是一家顶级社交媒体巨头，无需多介绍。这家脸书和 Instagram 巨头拥有一个稳固的核心业务，像少数其他公司一样产生现金流。因此，该公司最近的飙升主要归功于基本面——这是许多顶级成长股所不能夸耀的。</p>
</div><p>In the company’s most recent quarter, Meta announced it would be expanding its AI spending spree, now forecasting to spend between $37 and $40 billion this year alone. This heightened capital spending plan is a move CEO Mark Zuckerberg is making to transform Meta into a top AI company globally by year end.</p>
<div class="lb-trans"><p>在公司最近的一个季度中，Meta 宣布将扩大其人工智能支出，现在预计仅今年将花费 370 至 400 亿美元。这一加大的资本支出计划是首席执行官马克·扎克伯格为了在年底前将 Meta 转变为全球顶尖人工智能公司而采取的举措。</p>
</div><p>That’s an ambitious goal, and it’s certainly one investors are paying attention to. However, that’s to say nothing of the company’s strong core business which has seen significant digital advertising growth fueled by widespread internet and smartphone use. The company’s Q2 2024 revenue of $39.1 billion was 136% higher than five years prior, with the global digital ad market expected to grow at a 15.5% annual rate. Meta’s operating margin came in at an impressive 38%, with its apps segment achieving a 50% margin, highlighting Meta’s significant profitability and growth potential.</p>
<div class="lb-trans"><p>这是一个雄心勃勃的目标，投资者肯定在关注。然而，这并不是说该公司强劲的核心业务就无足轻重。该公司的 Q2 2024 年收入为 391 亿美元，比五年前高出 136%，全球数字广告市场预计以 15.5% 的年增长率增长。Meta 的营运利润率达到令人印象深刻的 38%，其应用部门实现了 50% 的利润率，突显了 Meta 的显著盈利能力和增长潜力。</p>
</div><p>Meta generated $23.4 billion in free cash flow in the first half of the year, which CEO Mark Zuckerberg invested in stock buybacks and dividends. A leader in tech and internet sectors, Meta is heavily investing in AI, including the Meta AI chatbot for creating images and handling various user prompts. Meta’s strong competitive edge is reinforced by its vast user base of 3.27 billion daily app users, enhancing its appeal to advertisers through significant engagement and network effects.</p>
<div class="lb-trans"><p>Meta 在上半年创造了 234 亿美元的自由现金流，首席执行官马克·扎克伯格将其投资于股票回购和股息。作为科技和互联网领域的领导者，Meta 正在大力投资于人工智能，包括 Meta AI 聊天机器人用于创建图像和处理各种用户提示。Meta 庞大的用户群体达到了 32.7 亿日活跃应用用户，通过显著的参与度和网络效应增强了其对广告商的吸引力。</p>
</div><h2>Johnson &amp; Johnson (JNJ)</h2>
<div class="lb-trans"><h2>强生（Johnson &amp; Johnson）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2021/02/imageForEntry20-M70.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2021/02/imageForEntry20-M70.jpg"/></p>
<p>Johnson &amp; Johnson sign outside of one of the company’s office buildings</p>
<div class="lb-trans"><p>强生（Johnson &amp; Johnson）标志在公司办公楼外的标志牌上</p>
</div><p><strong>Johnson &amp; Johnson</strong> (NYSE:JNJ) is known for its stability and reliable dividends, and continues to be a strong pick for dividend investors. Despite recent legal issues and the spin-off of its consumer health division, the company maintains a diverse revenue base in the pharmaceuticals, medical devices, and consumer products sectors. With a 3.1% dividend yield and a five-year dividend growth rate of more than 6%, JNJ stock offers consistent dividend growth and a resilient stock price. This makes the pharma giant appealing to many investors looking to compound their gains over time via dividend appreciation.</p>
<div class="lb-trans"><p><strong>强生（Johnson &amp; Johnson）</strong>（纽约证券交易所：JNJ）以其稳定性和可靠的股息而闻名，并继续是股息投资者的强劲选择。尽管最近存在法律问题并且分拆了其消费者健康部门，但该公司在制药、医疗器械和消费品领域保持着多样化的收入基础。JNJ 股票的股息率为 3.1%，五年股息增长率超过 6%，为投资者提供持续的股息增长和弹性股价。这使得这家制药巨头对许多寻求通过股息增值来复利其收益的投资者具有吸引力。</p>
</div><p>Notably, Johnson &amp; Johnson recently agreed to acquire V-Wave Ltd., a company developing heart failure treatments, for a $600 million up-front payment as well as potential additional payments up to $1.1 billion. V-Wave will become part of Johnson &amp; Johnson MedTech, enhancing its role in cardiovascular innovation and expanding its market presence.</p>
<div class="lb-trans"><p>值得注意的是，强生最近同意收购 V-Wave Ltd.，一家开发心力衰竭治疗方案的公司，支付了 6 亿美元的前期款项以及最高达 11 亿美元的额外支付。V-Wave 将成为强生医疗技术的一部分，增强其在心血管创新领域的作用并扩大其市场份额。</p>
</div><p>The stock’s stable performance is supported by strong earnings and a focus on high-growth areas like oncology and immunology. Johnson &amp; Johnson’s recent spin-off of Kenvue has allowed J&amp;J to sharpen its focus on core businesses, potentially enhancing growth. Analysts are optimistic, with upgrades following the Kenvue split. I think the company’s robust drug pipeline is likely to boost revenue, as ongoing legal resolutions add further stability to this name.</p>
<div class="lb-trans"><p>该股票稳定的表现得到了强劲的收益和对高增长领域（如肿瘤学和免疫学）的关注的支持。强生最近分拆 Kenvue，使 J&amp;J 能够专注于核心业务，潜在增强增长。分拆后，分析师持乐观态度。我认为公司强大的药物管线可能会提升收入，而持续的法律解决方案将进一步稳定这一名称。</p>
</div><h2>Pfizer (PFE)</h2>
<div class="lb-trans"><h2>辉瑞（Pfizer）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2021/12/imageForEntry83-3Qa.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2021/12/imageForEntry83-3Qa.jpg"/></p>
<p>Pfizer logo outsize of one of the company’s buildings</p>
<div class="lb-trans"><p>辉瑞标志在公司大楼外</p>
</div><p>In early 2024, <strong>Pfizer</strong> (NYSE:PFE) saw a rise in non-COVID revenues from key products like Prevnar and Eliquis. The company also had a number of notable product launches and acquisitions, including the purchase of Nurtec and Seagen assets. This trend is expected to persist over the long-term. But that’s not to say Pfizer isn’t concerned about its bottom line. With ongoing cost-cutting and restructuring plans underway, Pfizer aimed to save $4 billion in 2024.</p>
<div class="lb-trans"><p>2024 年初，<strong>辉瑞</strong>（纽约证券交易所：PFE）看到了来自 Prevnar 和 Eliquis 等关键产品的非 COVID 收入增长。该公司还进行了多项重要产品推出和收购，包括收购 Nurtec 和 Seagen 资产。这一趋势预计将在长期内持续。但这并不意味着辉瑞不关心其底线。随着持续进行的削减成本和重组计划，辉瑞旨在在 2024 年节省 40 亿美元。</p>
</div><p>The company continues to offer a robust 5.8% dividend yield, maintaining its commitment to regular payouts for income investors who are happily paid to wait for another bull market in the big pharma space.</p>
<div class="lb-trans"><p>该公司继续提供强劲的 5.8% 股息率，坚定地致力于定期支付给收入投资者，这些投资者很高兴等待大型制药领域的另一波牛市。</p>
</div><p>In the company’s recent earnings report, Pfizer raised its 2024 adjusted EPS guidance to $2.45-$2.65, up from $2.25, and increased its revenue forecast to $59.5-$62.5 billion, a 4% midpoint rise from 2023. The stock’s appeal lies in its sector leadership, innovation track record, and compelling value, with a forward P/E ratio of 11-times and a high dividend yield of 5.8%, based on a $0.42 quarterly payout.</p>
<div class="lb-trans"><p>在公司最近的财报中，辉瑞将其 2024 年调整后的每股收益指引提高至 2.45 美元至 2.65 美元，高于 2.25 美元，并将其营收预测提升至 595 亿至 625 亿美元，较 2023 年增长 4%。该股票的吸引力在于其行业领先地位、创新记录和引人注目的价值，前瞻市盈率为 11 倍，股息率高达 5.8%，基于每季度 0.42 美元的股息。</p>
</div><p>The company aims to restore investor confidence by showing progress in its long-term strategy. In Q2 earnings, revenue grew by 3% year-over-year, or 14% excluding the declining COVID-19 programs, Comirnaty and Paxlovid. This growth was fueled by strong sales of Vyndaqel, Eliquis, and the recently acquired Seagen, as well as increased demand for Nurtec. Pfizer’s cost realignment efforts, targeting $4 billion in savings by year-end, contributed to the success, with Q2 adjusted EPS of $0.60 exceeding Wall Street’s $0.46 estimate.</p>
<div class="lb-trans"><p>公司旨在通过展示其长期战略取得进展来恢复投资者信心。在第二季度财报中，营收同比增长 3%，或者在排除下降的 COVID-19 项目 Comirnaty 和 Paxlovid 后增长 14%。这一增长得益于 Vyndaqel、Eliquis 和最近收购的 Seagen 的强劲销售，以及对 Nurtec 需求的增加。辉瑞的成本调整努力旨在到年底节省 40 亿美元，为成功做出了贡献，第二季度调整后每股收益为 0.60 美元，超过了华尔街的 0.46 美元预期。</p>
</div><h2><strong>Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)</strong></h2>
<div class="lb-trans"><h2><strong>参加这个退休问卷，立即与顾问匹配（赞助内容）</strong></h2>
</div><p>Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.</p>
<div class="lb-trans"><p>您准备好退休了吗？规划退休可能让人感到不知所措，这就是为什么今天与一位受托人理财顾问讨论您的目标可能是个好主意。</p>
</div><p>Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.</p>
<div class="lb-trans"><p>从 SmartAsset 这里开始参加这个退休问卷，它将在 5 分钟内为您匹配最多 3 位服务您所在地区及周边地区的理财顾问。Smart Asset 目前每月为超过 5 万人提供匹配。</p>
</div><p>Click here now to get started.</p>
<div class="lb-trans"><p>立即点击这里开始。</p>
</div><p>The post 3 of the Best Long-Term Stocks to Buy Now and Hold Forever appeared first on 24/7 Wall St..</p>
<div class="lb-trans"><p>这篇文章最初发表在 24/7 Wall St.上，介绍了目前值得长期持有的 3 支最佳股票。</p>
</div>

3 of the Best Long-Term Stocks to Buy Now and Hold Forever

- 长期投资需要选择适合风险偏好的股票，坚持并耐心等待。
- Meta Platforms（META）是一家社交媒体巨头，致力于成为全球顶尖人工智能公司。
- Johnson & Johnson（JNJ）以其稳定性和可靠的股息而闻名，近期收购 V-Wave Ltd.，加强心衰治疗领域。
- 辉瑞（PFE）在非 COVID 产品收入上升，持续进行产品推出和收购，同时进行成本削减和重组计划。

三只现在购买并长期持有的最佳股票